Investments, Funding & Disinvestment

Alfasigma will pay GSK USD 300 million upfront, with an additional USD 100 million due upon US Food and Drug Administration (FDA) approval.

Rather than consolidating operations through plant closures, EMS intends to retain Medley’s existing facilities and invest in future expansion.

SmartHeart can cut the number of required breath-holds for basic views by up to 75%, making the examination considerably more comfortable for those being scanned.

Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.

The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.

The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.

The project will renovate and equip diagnostic laboratories, wastewater monitoring facilities, and environmental surveillance laboratories across six participating countries.

The venture aims to deliver comprehensive active pharmaceutical ingredient (API) services, covering everything from initial development stages through full-scale commercial production.

The company formalized its commitment with South Korea’s Ministry of Health and Welfare to enhance the bio-healthcare industry by supporting international clinical trials and advancing research for innovative medicines.

The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.